The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the Serum Institute of India (SII) have announced that they will start production of the Sputnik-V vaccine in India.
The first batch of the Sputnik-V vaccine is expected to be produced in the Serum Institute facilities from September. They plan to manufacture over 300 million doses of the vaccine annually in India.
As part of the technology transfer process, SII has already received cell and vector samples from the Gamaleya Center. With the import approved by the Drug Controller General of India (DCGI), the cultivation process has also begun.
SII already manufactures the Covishield vaccine developed by AstraZeneca and Oxford along with the Covovax vaccine developed by Novavax. SII is also conducting studies with Codagenix in the UK.
RDIF had previously made agreements with a number of pharmaceutical companies in India (Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen) to produce the Russian vaccine.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said, “RDIF is excited to partner with Serum Institute of India, the world’s largest vaccine manufacturer. This strategic partnership is an important step towards significantly increasing our production capacities and is a perfect example of pooling strengths and know-how to save lives both in India and around the world. In view of the ongoing technology transfer, we expect that the first batches of the vaccine will be manufactured together with SII in the coming months. “
Adar Poonawalla, CEO of the Serum Institute of India, said, “I am excited to be working with RDIF to manufacture the Sputnik vaccine. We hope to produce millions of cans in the coming months with test batches starting in September. With high efficacy and a good safety profile, it is critical that the Sputnik vaccine is fully accessible to people across India and around the world. Given the uncertainty of the virus, it is important that international institutes and governments work together to further intensify our fight against the pandemic. “
The Russian Sputnik-V vaccine has been registered in 67 countries worldwide with a total population of over 3.5 billion people. The data received from regulators of a number of countries during the vaccination of the population, including Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, United Arab Emirates and others, shows that Sputnik V is one of the safest and most effective vaccines against the coronavirus is.
Also read | How Covid-19 numbers warn of “vengeance trips”
Also read | Third wave of Covid inevitable: IMA is sounding the alarm about reopening tourism
إرسال تعليق